Ctt Pharmaceutic Financials
This page shows Ctt Pharmaceutic (CTTH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Ctt Pharmaceutic does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Ctt Pharmaceutic reported a net loss of $672K while operations used $72K of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Ctt Pharmaceutic reported -$672K in net income in fiscal year 2014. This represents a decrease of 3454.3% from the prior year.
Not reported for fiscal year 2014.
Not reported for fiscal year 2014.
Not reported for fiscal year 2014.
Cash & Balance Sheet
Ctt Pharmaceutic held $81K in cash as of fiscal year 2014; long-term debt is not reported for that period.
Not reported for fiscal year 2014.
Not reported for fiscal year 2014.
Margins & Returns
Ctt Pharmaceutic's ROE was -45.0% in fiscal year 2014, measuring profit generated per dollar of shareholder equity.
Not reported for fiscal year 2014.
Not reported for fiscal year 2014.
Not reported for fiscal year 2014.
Capital Allocation
None of these metrics is reported for fiscal year 2014.
CTTH Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q3'15 | Q2'15 | Q1'15 | Q4'14 | Q3'14 | Q2'14 | Q1'14 | Q4'13 |
|---|---|---|---|---|---|---|---|---|
| SG&A Expenses | $15K+234.4% | $4K-87.2% | $35K | N/A | $13K+1313.3% | $916+1.0% | $907 | N/A |
| Operating Income | N/A | N/A | -$337K | N/A | N/A | -$22K-1234.2% | -$2K | N/A |
| Net Income | -$342K+5.7% | -$363K-7.6% | -$337K | N/A | -$43K-4595.2% | -$920+45.0% | -$2K | N/A |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | $0.00 | $0.00-100.0% | $0.02 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, Interest Expense, Income Tax.
CTTH Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q3'15 | Q2'15 | Q1'15 | Q4'14 | Q3'14 | Q2'14 | Q1'14 | Q4'13 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $922K-22.1% | $1.2M-16.6% | $1.4M-14.6% | $1.7M+1171.4% | $131K-42.5% | $228K+1221.5% | $17K | $0 |
| Current Assets | $922K-3.8% | $959K-8.0% | $1.0M-0.7% | $1.0M | N/A | N/A | N/A | $6K |
| Cash & Equivalents | $32K-30.3% | $46K-37.3% | $73K-9.5% | $81K-35.2% | $125K+3315.6% | $4K-19.3% | $5K | $0 |
| Accounts Receivable | $5K0.0% | $5K0.0% | $5K0.0% | $5K | N/A | N/A | N/A | N/A |
| Total Liabilities | $184K+17.6% | $156K-26.1% | $212K+24.9% | $169K+36.0% | $125K-12.2% | $142K-49.3% | $280K+854.5% | $29K |
| Total Equity | $738K-28.1% | $1.0M-14.9% | $1.2M-19.1% | $1.5M+24182.4% | $6K-92.8% | $86K+132.6% | -$263K-795.7% | -$29K |
| Retained Earnings | -$1.9M-21.8% | -$1.6M-30.1% | -$1.2M-38.9% | -$867K-274.7% | -$231K | N/A | N/A | -$195K |
Not reported in any period shown, so not listed: Inventory, Goodwill, Current Liabilities, Long-Term Debt.
CTTH Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q3'15 | Q2'15 | Q1'15 | Q4'14 | Q3'14 | Q2'14 | Q1'14 | Q4'13 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$16K+46.7% | -$29K+26.5% | -$40K+15.3% | -$47K-93.5% | -$24K+15.8% | -$29K-8608.2% | -$330-57.9% | -$209 |
| Investing Cash Flow | N/A | N/A | N/A | -$1-100.0% | $271K+283.5% | -$148K-618.0% | $29K-77.2% | $125K |
| Financing Cash Flow | -$959-134.4% | $3K-90.2% | $29K | N/A | -$5K-101.3% | $387K+7833.3% | $5K | $0 |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
CTTH Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q3'15 | Q2'15 | Q1'15 | Q4'14 | Q3'14 | Q2'14 | Q1'14 | Q4'13 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -46.3%-11.0pp | -35.3%-7.4pp | -27.9% | N/A | -702.6%-701.5pp | -1.1% | N/A | N/A |
| Return on Assets | -37.1%-6.4pp | -30.6%-6.9pp | -23.8% | N/A | -33.0%-32.6pp | -0.4%+9.3pp | -9.7% | N/A |
| Debt-to-Equity | 0.25+0.1x | 0.150.0x | 0.18+0.1x | 0.11-20.2x | 20.27+18.6x | 1.66 | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Current Ratio, FCF Margin.
Similar Companies
Where Ctt Pharmaceutic Ranks
Frequently Asked Questions
Is Ctt Pharmaceutic profitable?
No, Ctt Pharmaceutic (CTTH) reported a net income of -$672K in fiscal year 2014.
What is Ctt Pharmaceutic's return on equity (ROE)?
Ctt Pharmaceutic (CTTH) has a return on equity of -45.0% for fiscal year 2014, measuring how efficiently the company generates profit from shareholder equity.
What is Ctt Pharmaceutic's operating cash flow?
Ctt Pharmaceutic (CTTH) recorded an outflow of $72K in operating cash flow during fiscal year 2014, representing cash used by core business activities.
What are Ctt Pharmaceutic's total assets?
Ctt Pharmaceutic (CTTH) had $1.7M in total assets as of fiscal year 2014, including both current and long-term assets.
What is Ctt Pharmaceutic's debt-to-equity ratio?
Ctt Pharmaceutic (CTTH) had a debt-to-equity ratio of 0.11 as of fiscal year 2014, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Ctt Pharmaceutic's return on assets (ROA)?
Ctt Pharmaceutic (CTTH) had a return on assets of -40.4% for fiscal year 2014, measuring how efficiently the company uses its assets to generate profit.
How does Ctt Pharmaceutic's liquidity compare with its operating cash outflow?
At the end of fiscal year 2014, Ctt Pharmaceutic (CTTH) held $81K in cash, cash equivalents and investments, and reported an operating cash outflow of $72K over that year. Dividing the one by the other, the reported balance equals about 13 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Are Ctt Pharmaceutic's earnings high quality?
Ctt Pharmaceutic (CTTH) reported a net loss of $672K while operations used $72K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.